A healthcare agency is priced on headcount. The rate card is built from salaries plus overhead plus margin, and the invoice is a count of hours against roles. That structure has a logic to it: when every asset is made by hand, the only way to make more is to hire more, and the only way to protect quality is to add layers of review over the people doing the work.

The consequence is that the client buys capacity rather than output. You are quoted for a team, and the team's utilisation becomes a shared problem. Coordination gets billed. Status meetings get billed. Rebuilding an asset that already exists in an approved form somewhere in the organisation gets billed, because finding it costs more hours than remaking it.

What changes when production is not the constraint

If assembly is no longer the expensive part, the pyramid has nothing to hold up. What remains scarce is judgment: knowing what the piece has to say, whether the evidence supports it, and how a reviewer will read it. That work does not scale with headcount, and it does not need coordinators.

So the unit of sale changes. Instead of buying hours and hoping the output arrives, you buy the finished deliverable at a fixed price, with the review documentation attached. The risk of estimating the work moves to the producer, which is where it belongs. If a piece takes longer than expected, that is a production problem, not a change order.

What does not change

Medical accuracy, fair balance and safety information do not get faster because production did. They get more important, because volume goes up. A model that produces more assets without producing more review documentation is not cheaper, it is a liability moved downstream onto the people who sign off.

That is why the pack matters more than the speed: claims matrix, annotated references, safety placement rationale, change log. The finished asset is the product. The documentation is what makes it review ready, and review ready is the only definition of finished that means anything in this industry.

Veeva Pulse field data reported in 2025 that about eighty per cent of approved pharmaceutical content is rarely or never used. The figure is easy to quote and easy to misread, so it is worth being careful about what it does and does not say.

It does not say that eighty per cent of content was badly made. Most of it went through the same brief, the same production and the same review as the twenty per cent that gets used. It says that the commissioning decision, made months earlier, did not match what field teams and customers turned out to need.

Why the old economics produced this

When each asset is expensive and slow, you commission in bulk and in advance. Annual planning locks a content list before the year's questions are known. Nobody wants to go back for a second budget round, so the list is padded. Then the review layer absorbs the whole batch at once, at a documented cost of roughly two and a half to five thousand US dollars per asset in manual review, and the organisation has paid twice for material it will not use.

The waste is not really in production. It is in the commitment: choosing what to make while the information that would tell you what to make does not exist yet.

Commission later, in smaller pieces

If a deliverable costs a third as much and arrives in ten to fifteen business days, the planning horizon can shorten. You commission when the need is visible rather than when the budget cycle demands a list. Fewer assets get made, more of them get used, and the review layer handles a stream instead of a flood.

Modular content helps the same way. Claims, references, safety text and message modules held in an approved library mean the next asset is assembled from parts that have already passed review, rather than written from scratch and re reviewed line by line.

The test is simple, and it is worth running on your own portfolio: of the assets approved in the last twelve months, how many were used more than twice? The answer usually explains the budget better than any rate card negotiation will.

Review ready is used loosely. In our statements of work it has a specific meaning: the asset arrives with the four documents a reviewer needs in order to decide, and nothing in it depends on a conversation that was not written down.

The claims matrix

Every claim in the asset, listed as its own row, with the reference that supports it and the exact location where it appears. A reviewer should never have to search the asset to find what a row refers to, and should never find a claim in the asset that is missing from the matrix. Rows we believe need a medical decision are flagged as such rather than quietly resolved.

Annotated references

The source documents, with the supporting passage marked in each one. Not a bibliography. If the claim rests on a table, the table is marked. If it rests on a subgroup, the subgroup is marked, and the limitation is noted next to it.

ISI placement rationale

Where the important safety information sits, at what prominence, and why. For digital assets this covers behavior as well as position: what a reader sees before scrolling on a phone, what happens on a small screen, and how the safety text behaves relative to the promotional claim it accompanies.

Change log

What changed between rounds, who asked for it, and what else it affected. In a modular library this is what stops an approved fragment being edited in one asset and left stale in five others.

One thing the pack deliberately does not contain is our opinion on whether the claim should be approved. We produce compliant drafts and the evidence behind them. The decision, and the accountability for it, sits with your medical, legal and regulatory reviewers.